Home » Stocks » CRMD

CorMedix, Inc. (CRMD)

Stock Price: $5.97 USD -0.28 (-4.48%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 236.69M
Revenue (ttm) 253,438
Net Income (ttm) -23.69M
Shares Out 36.33M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $5.97
Previous Close $6.25
Change ($) -0.28
Change (%) -4.48%
Day's Open 6.28
Day's Range 5.95 - 6.30
Day's Volume 136,289
52-Week Range 3.86 - 18.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

New York, New York--(Newsfile Corp. - July 29, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD).Shar...

3 hours ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - July 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CorMedix Inc. ("CorMed...

5 hours ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 29, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased CorMedix Inc. ("CorM...

7 hours ago - Newsfile Corp

NEW YORK, July 29, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a Lead Plaintiff motion in a securities class actio...

8 hours ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)-- #CRMD--Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against CorMedix Inc. (NASDAQ: CRMD) and September 20 Deadline

8 hours ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $CRMD #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CorMedix Inc. (“CorMedix” ...

9 hours ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CRMD #investors--The Law Offices of Frank R. Cruz Announces Investigation of CorMedix Inc. (CRMD) on Behalf of Investors

1 day ago - Business Wire

New York, New York--(Newsfile Corp. - July 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that t...

1 day ago - Newsfile Corp

NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) and certain of its officers....

1 day ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of CorM...

1 day ago - Newsfile Corp

SAN DIEGO--(BUSINESS WIRE)---- $CRMD #CRMD--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of CorMedix Inc. (NASDAQ: CRMD) between July ...

1 day ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $CRMD #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...

1 day ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $CRMD #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) investors concern...

1 day ago - Business Wire

BERKELEY HEIGHTS, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

1 day ago - GlobeNewsWire

San Diego, California--(Newsfile Corp. - July 27, 2021) - The CorMedix class action lawsuit charges CorMedix Inc. (NASDAQ: CRMD) and certain of its top executives with violations of the Securities Excha...

2 days ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $CRMD #CRMD--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc.

2 days ago - Business Wire

NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CorMedix Inc. ...

3 days ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 26, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that ...

3 days ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $CRMD #CRMD--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc.

3 days ago - Business Wire

New York, New York--(Newsfile Corp. - July 26, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cor...

3 days ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CorMedix Inc. (NASDAQ: CRMD...

3 days ago - Business Wire

NEW YORK, July 26, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or "the...

3 days ago - PRNewsWire

SAN DIEGO, July 26, 2021 /PRNewswire/ -- The CorMedix class action lawsuit charges CorMedix Inc. (NASDAQ: CRMD) and certain of its top executives with violations of the Securities Exchange Act of 1934 a...

3 days ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against CorMedix Inc. (“CorMedix” or the...

6 days ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers of CorMedix Inc. (NASDAQ: CRMD) securities between July 8, 2020 and May 13, 2021, inclusive (“Class Period”) have u...

6 days ago - Business Wire

New York, New York--(Newsfile Corp. - July 23, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of i...

6 days ago - Newsfile Corp

NEW YORK, July 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD) and certain of its officers....

1 week ago - PRNewsWire

BERKELEY HEIGHTS, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

1 month ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

1 month ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and t...

2 months ago - GlobeNewsWire

Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported ...

Other stocks mentioned: BNGO, ELOX
2 months ago - Benzinga

CorMedix (CRMD) delivered earnings and revenue surprises of -11.11% and 46.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

2 months ago - GlobeNewsWire

Thomas Nusbickel to join CorMedix as Chief Commercial Officer; Brings significant experience in renal product launches and commercialization Thomas Nusbickel to join CorMedix as Chief Commercial Officer...

2 months ago - GlobeNewsWire

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BERKELEY HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

3 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

3 months ago - GlobeNewsWire

CorMedix (CRMD) delivered earnings and revenue surprises of 17.39% and -11.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

3 months ago - GlobeNewsWire

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to contac...

4 months ago - PRNewsWire

BERKELEY HEIGHTS, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

4 months ago - GlobeNewsWire

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc.  ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to conta...

4 months ago - PRNewsWire

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

4 months ago - GlobeNewsWire

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc.  ("CorMedix" or the "Company") (NASDAQ: CRMD).  Such investors are advised to cont...

4 months ago - PRNewsWire

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

4 months ago - GlobeNewsWire

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Surface Oncology, Inc. (NASDAQ: SURF) and CorMedix Inc. (NASDAQ: CRMD) are among the biggest movers among health care stocks Tuesday.

Other stocks mentioned: ANPC, SURF
4 months ago - Benzinga

BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

4 months ago - GlobeNewsWire

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

The FDA gave a thumbs-down to CorMedix's antibacterial/anti-fungal catheter lock.

4 months ago - The Motley Fool

The FDA has issued a Complete Response Letter for CorMedix Inc's (NASDAQ: CRMD) marketing application seeking approval for DefenCath (taurolidine/heparin catheter lock solution) for catheter-related blo...

4 months ago - Benzinga

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology... [Read more...]

Industry
Biotechnology
IPO Date
Mar 25, 2010
CEO
Khoso Baluch
Employees
35
Stock Exchange
NASDAQ
Ticker Symbol
CRMD
Full Company Profile

Financial Performance

In 2020, CorMedix's revenue was $239,231, a decrease of -15.55% compared to the previous year's $283,266. Losses were -$22.03 million, 34.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CorMedix stock is "Buy." The 12-month stock price forecast is 20.30, which is an increase of 240.03% from the latest price.

Price Target
$20.30
(240.03% upside)
Analyst Consensus: Buy